NCT02606136 - Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2016

Primary Completion Date

May 7, 2020

Study Completion Date

August 9, 2023

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Pamrevlumab

Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials

Trial Locations (10)

The Children's Hospital of Philadelphia, Philadelphia

Rare Disease Research, Atlanta

Cincinnati Children's Hospital Medical Center, Cincinnati

Washington University in St. Louis School of Medicine, St Louis

Children's Medical Center Ambulatory Care Pavilion, Dallas

Children's Hospital Colorado, Aurora

David Geffen School of Medicine at UCLA, Los Angeles

University of California San Francisco - Benioff Children's Hospital, San Francisco

Shriner's Hospital for Children - Portland, Portland

Boston Children's Hospital, Boston